<?xml version="1.0" encoding="UTF-8"?>
<p>Drug repurposing screens, especially screening of existing drugs, was viewed as an alternative and efficient method of speeding up drug development [
 <xref rid="B14-viruses-11-00742" ref-type="bibr">14</xref>]. Therefore, a Food and Drug Administration (FDA)-approved drug library has recently been widely used for successfully screening inhibitors against both DNA and RNA viruses, including Ebola (EBOV) [
 <xref rid="B15-viruses-11-00742" ref-type="bibr">15</xref>,
 <xref rid="B16-viruses-11-00742" ref-type="bibr">16</xref>], Zika (ZIKV) [
 <xref rid="B14-viruses-11-00742" ref-type="bibr">14</xref>,
 <xref rid="B17-viruses-11-00742" ref-type="bibr">17</xref>,
 <xref rid="B18-viruses-11-00742" ref-type="bibr">18</xref>], and Hepatitis B (HBV) [
 <xref rid="B19-viruses-11-00742" ref-type="bibr">19</xref>] viruses.
</p>
